Jiangsu Code Biomedical Technology Co., Ltd is a high-tech enterprise integrating research, development, production and sales of biotechnology products and biopharmaceuticals. Code is committed to the development of in vitro diagnostic techniques, detection of new targets and the development of biotherapeutics. We have strong R&D and management team at home and abroad including “Thousand Talents Program" expert. The company has cooperated with internationally renowned biopharmaceutical companies in the research and development of cancer diagnosis and treatment, and has more than 10 international and domestic invention patents. Moreover, we also have theoretical and technical support from the research group of The First Affiliated Hospital Of Nanjing Medical University (Jiangsu Province Hospital).     

Code independently discovered new biomarkers for the critical illness diagnosis and treatment, and developed individualized and precise medical diagnostic methods for clinical use. Currently, Tumor Specific Protein 70 Antibody Reagent (Immunohistochemistry), Tumor Specific Protein 70 Detection Kit (ELISA), Circulating Tumor Cells Detection Kit (SP70 Targeted Flow Cytometry Assay), Pleural Effusion Tumor Cells Detection Kit (Immunomagnetic Beads Capture Based Liquid Biopsy) and Plasma cell-free DNA (cfDNA) Quantitative Detection Kit (Quantitative Real-Time Polymerase Chain Reaction Assay) are mainly available. We established a sound industrialization system for R&D, production and sales in the field of biomedicine, while pursuing strict quality, safety and value standards to serve human health.

our kit with CE certification: